The U.S. Department of Justice has filed a motion in federal court seeking an immediate asset freeze and the appointment of a receiver for telehealth company Zealthy and its chief executive, Kyle Robertson, over allegations of fraudulent prescribing practices and deceptive business conduct. The filing, submitted to the U.S. District Court for the Southern District of Novel York, accuses the company of orchestrating a scheme to illegally distribute controlled substances through telehealth consultations that lacked proper medical oversight. According to the DOJ, Zealthy’s operations involved prescribing opioids and other high-risk medications based on minimal or nonexistent patient evaluations, often relying on standardized questionnaires rather than meaningful clinical assessments.
The government’s motion asserts that Zealthy and Robertson engaged in a pattern of conduct designed to evade regulatory scrutiny while maximizing profits from high-volume prescribing. Prosecutors allege that the company utilized a network of loosely affiliated physicians who were incentivized to approve prescriptions rapidly, sometimes in under 90 seconds, without verifying patient identity or medical history. These practices, the DOJ contends, violated the Controlled Substances Act, the Federal Food, Drug, and Cosmetic Act, and various anti-kickback statutes. The filing further claims that Zealthy misrepresented its compliance with state telehealth regulations and deceived both patients and pharmaceutical distributors about the legitimacy of its operations.
If granted, the requested asset freeze would prevent Zealthy from accessing its bank accounts or transferring property, while the appointment of a receiver would place an independent third party in control of the company’s operations to preserve assets and investigate potential wrongdoing. Such measures are typically sought in cases involving ongoing fraud where there is a risk of asset dissipation. The DOJ emphasized in its filing that the urgency of the situation stems from evidence suggesting Zealthy may be preparing to shut down or relocate funds overseas to avoid accountability.
Zealthy, which marketed itself as a convenient digital clinic offering same-day consultations and prescription delivery, operated primarily through a mobile app and website that promised patients access to treatments for anxiety, depression, weight loss, and pain management. The company claimed to serve thousands of patients across multiple states, though the exact number of individuals affected remains unspecified in the public filings. Internal communications referenced in the DOJ’s motion allegedly show discussions among company leaders about how to maximize prescription volume while minimizing time spent per patient encounter—a detail prosecutors cite as evidence of intent to prioritize profit over patient safety.
The case reflects broader federal efforts to curb abuses in the telehealth sector, which expanded rapidly during the COVID-19 pandemic under relaxed regulations that allowed for remote prescribing of controlled substances without an in-person examination. While many telehealth providers adopted responsible practices, regulators and law enforcement have increasingly warned about bad actors exploiting the shift to digital care for illicit prescribing. In 2023, the Drug Enforcement Administration issued warnings about fraudulent telehealth platforms prescribing opioids, stimulants, and other controlled substances based on minimal interaction, prompting a series of investigations and prosecutions nationwide.
To date, Zealthy has not issued a public response to the DOJ’s motion, and attempts to reach Kyle Robertson for comment were unsuccessful. The company’s website remains accessible as of the latest check, though it no longer accepts new patient sign-ups. Telehealth industry experts note that while legitimate providers continue to play a vital role in expanding access to care—particularly in underserved or rural areas—cases like this underscore the demand for stronger oversight mechanisms to prevent abuse.
The legal proceedings are expected to unfold over the coming months, with a hearing on the DOJ’s motion for asset freeze and receivership scheduled for May 15, 2024, before Judge Analisa Torres in the Southern District of New York. At that hearing, the court will consider whether there is sufficient evidence to justify the extraordinary relief requested by the government. Legal analysts note that granting a receivership at this stage is uncommon and typically reserved for cases where there is clear and present danger of fraud continuation or asset concealment.
For individuals who may have received prescriptions through Zealthy, health officials advise consulting with a licensed healthcare provider to review the appropriateness of any ongoing medications, particularly opioids, benzodiazepines, or stimulants. Patients are encouraged not to discontinue any prescribed medication abruptly without medical supervision. The Substance Abuse and Mental Health Services Administration (SAMHSA) offers a confidential, 24/7 helpline at 1-800-662-4357 for those seeking support or information about substance use and treatment options.
As the case develops, it may influence future regulatory approaches to telehealth prescribing, especially concerning controlled substances. Federal agencies including the DEA, the Department of Health and Human Services, and the Centers for Medicare & Medicaid Services have signaled increased scrutiny of digital health platforms to ensure patient safety without stifling innovation in remote care delivery.
Stay informed about this developing story by following updates from the U.S. Department of Justice’s Press Office and the Public Access to Court Electronic Records (PACER) system, where filings in the case United States v. Zealthy Inc. And Kyle Robertson are available for public review.
We invite readers to share thoughtful comments and perspectives below. If you have experience with telehealth services or concerns about online prescribing practices, your insights can aid inform broader conversations about access, safety, and accountability in digital health. Please share this article to help others stay informed.